A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR , a Multigenic, Recombinant Modified Vaccinia Ankara HIV-1 Vaccine Expressing Env gp 150/Gag/Pol, in HIV-uninfected Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) Plus Poly-ICLC (Hiltonol) (RV 365 / WRAIR #2006).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs MVA HIV vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 17 Feb 2016 Biomarkers information updated
- 14 Aug 2013 New trial record